GDF2 and pulmonary arterial hypertension: Causal variants in GDF2 (BMP9) were first described in adult-onset PAH patients by Gräf et al. [9], and subsequently reported in two studies describing GDF2 variants in respectively 6.7% and 1.1% of sporadic PAH patients [31].